Axio BioPharma

09/09/2025

Every breakthrough medicine starts as an idea at the lab bench. Too often, those ideas get stuck in the long and costly road to clinical manufacturing. At Axio BioPharma, we are changing that.

In less than a year, our Madison-based team has:
✅ Built a $30M+ sales pipeline
✅ Secured investment from partners like Chisos Capital and the Chemical Angel Network
✅ Grown a full-time team of scientists and business leaders
✅ Begun developing an AI model that can predict manufacturability in hours instead of months or years

Our mission is clear: make the path from concept to clinic faster, smarter, and more reliable. From antibodies today to gene editing, cell therapy, and mRNA tomorrow—the future of biomanufacturing is being written now.

A big thank-you to In Business Madison and Brittney Kenaston for spotlighting our journey.

Read the full story here:
👉 https://www.axiobiopharma.com/news/in-business-moving-from-the-lab-to-the-medicine-cabinet

07/17/2025

🧬 Axio BioPharma is redefining biotech..🔍

As a science-first CDMO, Axio blends deep immunology expertise with AI 🤖 to accelerate monoclonal antibody development from discovery to GMP manufacturing.

Their innovative platform helps biotech and pharma partners bring life-saving therapies to market faster, more efficiently, and at lower cost. 💉🌍

We’re honored to support a team that’s pushing the boundaries of what’s possible in science and medicine. 🙌

🔗 Learn more about their work: https://www.axiobiopharma.com/

06/11/2025

We’re heading to Boston for BIO 2025 next week!

Our CEO, Justin Byers, will be on-site and is looking to connect with:

✅ Biopharma companies focused on accelerating early development
✅ Resin manufacturers interested in being included in our AI-powered platform
✅ Teams with manufacturing data open to strategic collaboration

If you’re attending, reach out to set up a time to connect. We’re building the future of biologics, and we’d love to meet others who are too.

06/10/2025

Big news from the Axio BioPharma team!

We’ve just announced a new partnership with Likarda, a company doing amazing work in drug delivery and formulation. Their Core-Shell Spherification® (CSS®) hydrogel technology helps ensure biologics like antibodies are delivered more effectively and reliably.

By combining their tech with our AI-driven manufacturing platform, we’re making it faster and easier for life-saving biologics to move from the lab to patients.

Proud of what we’re building together.

📣 Read the full announcement: https://www.prnewswire.com/news-releases/axio-biopharma-and-likarda-announce-strategic-partnership-to-accelerate-biologic-drug-development-and-delivery-302475579.html

01/06/2025

We’re excited to announce our strategic partnership with eMBR Genomics! 🎉 Together, we’re bringing MKLP1 Pro™ antibodies to the global research community, advancing midbody remnant (MBR) research and the future of cancer diagnostics.

Learn more about this innovative collaboration: https://www.axiobiopharma.com/news-and-blog/embr-genomics-partners-with-axio-biopharma-to-manufacture-and-distribute-proprietary-mklp1-pro-antibodies

12/31/2024

🎉 Wishing You a Happy New Year from Axio BioPharma! 🎉

As 2024 comes to a close, we reflect on the incredible milestones we’ve achieved since our launch in August. 🚀

✅ Established Our Laboratory: Our lab in Madison, WI is fully operational, supporting small-scale protein manufacturing projects.

✅ First Programs Initiated: We've begun generating real-world data through 96-well plate-based production, setting the foundation for our predictive AI model.

✅ Built a Stellar Team: Our growing team includes top talent, including Jaclyn Mabry and David Marshall, who are driving innovation in our lab. We also have the guidance of our amazing advisors: Dr. Greg Bleck, Dr. Graham Brearley, and Alex Vodenlich.

✅ Accelerated Services: Offering small-scale parallel manufacturing with a focus on mAbs, we’re delivering faster solutions with our 4 week gene-to-protein turnaround times.

✅ Set Our Vision: We’re transforming biopharmaceutical manufacturing with our proprietary AI model that predicts robust, scalable processes and reduces development timelines from years to hours.

We couldn’t have done this without the incredible support of our team, advisors, consultants, and the community. Here’s to a 2025 filled with growth, innovation, and breakthroughs in bringing life-saving therapies to patients faster.

Let’s keep accelerating together! 🚀✨

12/24/2024

🎄 Happy Holidays from Axio BioPharma! 🎄

Wishing you and your loved ones a joyful and peaceful holiday season. At Axio BioPharma, we are grateful for the opportunity to partner with so many incredible people who share our mission of bringing life-saving therapies to patients faster.

Warm holiday wishes,
The Axio BioPharma Team 🎁✨

12/19/2024

Join Us at BIO Partnering JPM Week 2025!

Axio BioPharma is proud to attend BIO Partnering Week 2025, where innovation meets opportunity. We're accelerating mammalian protein development with rapid, cost-effective manufacturing solutions, helping companies bring life-saving therapies to patients faster.

🌟 Ready to partner? Schedule a meeting with us through the BIO partnering system to explore how Axio BioPharma can support your company’s goals. Let’s revolutionize the future of drug development together!

👉 Click here to schedule a meeting: https://login.partnering.bio.org/inova-business-platform/webclient/ #/bio/16303/company/188973

12/12/2024

🎉 Exciting news! Axio BioPharma is honored to be a recipient of the 2024 Forward Membership Program, awarded by Forward BIOLABS with support from the Wisconsin Economic Development Corporation (WEDC).

The program provides us with access to state-of-the-art coworking labs, and resources, helping accelerate our mission of delivering faster, more cost-effective antibody and protein manufacturing services.

✨We’re thrilled to be part of this vibrant biohealth ecosystem alongside so many innovative companies.

Thank you to Forward BIOLABS, WEDC, and the selection committee for this incredible opportunity!

🚀 Together, we’re shaping the future of biotech in Wisconsin and beyond.

🔗 Learn more: https://www.forwardbiolabs.org/forward-membership-release

Forward Memberships support early-stage biohealth companies with lab space, resources, and community to accelerate innovation 

10/31/2024

🌟 Exciting News! 🌟

Axio BioPharma's CEO, Justin Byers, will be pitching at the 2024 Early Stage Symposium in Madison, hosted by the Wisconsin Technology Council. Join us to hear about our rapid, data-driven approach to biopharmaceutical manufacturing and connect with innovators across the industry.

We’re looking forward to sharing Axio's journey and vision with the community—see you there!

📅 November 13-14
🔗 Register here to attend: https://wisconsintechnologycouncil.com/emerging-firms-will-pitch-over-two-days-at-2024-early-stage-symposium-in-madison/

09/20/2024

🎉 Axio BioPharma is now offering protein manufacturing services!

We’re excited to announce that Axio BioPharma is accepting monoclonal antibody (mAb) manufacturing projects. Our innovative small-scale manufacturing ensures efficient, reliable results and accelerated timelines for biopharma development. Learn more about our capabilities in our latest press release. ➡️ https://www.prnewswire.com/news-releases/axio-biopharma-launches-protein-manufacturing-services-302253594.html

09/13/2024

🚀 AXIO BioPharma is Open for Research Grade Antibody Projects!

We’re excited to offer Research Grade monoclonal antibody production with small-scale, parallel production capacities ranging from 50mL to 2L. Our flexible approach is designed to support early-stage discovery, helping you move faster and more efficiently.

Looking for cost-effective, small-scale production to accelerate your development? Let’s connect!

🔗 Book a meeting with us today: https://meetings.hubspot.com/justin-byers1